Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03305770 · ClinicalTrials.gov registry record · NA

DD T2 Daily Disposable Registration Trial

A NA study of Myopia and Refractive Errors, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
107
Enrollment target
6
Study locations

NCT03305770 is a NA study of Myopia and Refractive Errors that has completed, run by Alcon Research. The registered enrollment target is 107 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03305770, a NA study of Myopia and Refractive Errors, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
107 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to evaluate the performance of the investigational verofilcon A contact lens compared to the commercially available delefilcon A contact lens, by assessing visual acuity as the primary variable.

Conditions Studied

Interventions

  • DEVICE verofilcon A contact lenses
  • DEVICE delefilcon A contact lenses

Study Locations (6)

Florida

  • Alcon Investigative Site - Longwood
  • Alcon Investigative Site - Maitland

Tennessee

  • Alcon Investigative Site - Brentwood
  • Alcon Investigative Site - Memphis

California

  • Alcon Investigative Site - San Diego

Illinois

  • Alcon Investigative Site - Bloomington

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2017-10-12
Est. Completion 2018-02-21
Phase NA

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT03305770

The ClinicalTrials.gov registry entry for NCT03305770 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (60% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which verofilcon A contact lenses is the first listed.

NCT03305770 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Florida, Tennessee, California.

Frequently Asked Questions

What is clinical trial NCT03305770 about?

NCT03305770 is a clinical study titled "DD T2 Daily Disposable Registration Trial". The purpose of this study is to evaluate the performance of the investigational verofilcon A contact lens compared to the commercially available delefilcon A contact lens, by assessing visual acuity as the primary variable.

What is the current status of trial NCT03305770?

This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2017-10-12. Estimated completion is 2018-02-21.

What conditions does trial NCT03305770 study?

This clinical trial studies the following conditions: Myopia, Refractive Errors.

What interventions are being tested in trial NCT03305770?

The interventions under investigation include: verofilcon A contact lenses (DEVICE), delefilcon A contact lenses (DEVICE).

Who is sponsoring clinical trial NCT03305770?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03305770 being conducted?

This trial has 6 study locations across California, Florida, Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.